Business
Definium Therapeutics Appoints Roger Adsett to Board of Directors
Seasoned biopharmaceutical leader brings deep commercial, operational, and launch expertise to support Definium’s next phase of growth NEW YORK--(BUSINESS
About this update from Definium Therapeutics, Inc.
[{"type":"text","content":"\nSeasoned biopharmaceutical leader brings deep commercial, operational, and launch expertise to support Definium’s next phase of growth\n\n\n NEW YORK--(BUSINESS WIRE)--\nDefinium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately.\n\n\n“We are thrilled to welcome Roger to our Board of Directors,” said Rob Barrow, Chief Executive Officer of Definium Therapeutics. “Roger is a respected and proven leader with deep experience building high-performing commercial organizations and guiding transformational therapies from launch to meaningful market impact. At Insmed, he’s led the development of world-class commercial and operational capabilities supporting the company on its mission to transform the lives of patients facing serious diseases. His ability to translate innovative science into disciplined, large-scale commercial execution will be especially valuable as we approach three anticipated Phase 3 readouts in 2026 and prepare to bring transformative therapies to patients.”\n\n\nMr. Adsett is a highly accomplished biopharmaceutical executive with more than two decades of experience leading landmark drug launches, scaling global commercial organizations, and helping companies establish leadership positions within their therapeutic areas, including specialty, rare disease, and primary care markets.\n\n\n“I’ve admired Definium's commitment to scientific rigor and its ambition to redefine the treatment landscape for people living with mental health disorders,” said Mr. Adsett. “It’s an honor to join the Board at this pivotal moment and to collaborate with leaders committed to advancing compelling clinical research into therapies that drive meaningful value for patients and shareholders.”\n\n\nAbout Roger Adsett\n\n\nMr. Adsett currently serves as Chief Operating Officer of Insmed, a position he has held since November 2019 after serving as Chief Commercial Officer from 2016 to 2019. In these roles, he has overseen commercial strategy and execution, operational excellence, and enterprise-wide growth initiatives. He played a central role in building Insmed’s global commercial organization and supporting the launch and growth of ARIKAYCE® and BRINSUPRI® establishing Insmed as a fully integrated commercial biopharmaceutical company. Pr...